BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Giaccone L, Festuccia M, Marengo A, Resta I, Sorasio R, Pittaluga F, Fiore F, Boccadoro M, Rizzetto M, Bruno B, Marzano A. Hepatitis B Virus Reactivation and Efficacy of Prophylaxis with Lamivudine in Patients Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2010;16:809-17. [DOI: 10.1016/j.bbmt.2009.12.533] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Clerico M, Dogliotti I, Ghione P, Zilioli VR, Merli F, Botto B, Al Essa W, Battaglini M, Grimaldi D, Cervi L, Ragaini S, Ferrero S, Peri V, De Luca G, Marzano A, Cavallo F. HBV Reactivation in Patients with Past Infection Affected by Non-Hodgkin Lymphoma and Treated with Anti-CD20 Antibody Based Immuno-Chemotherapy: A Multicenter Experience. JPM 2022;12:285. [DOI: 10.3390/jpm12020285] [Reference Citation Analysis]
2 Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J; Collaborators:. S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11). Z Gastroenterol 2021;59:691-776. [PMID: 34255317 DOI: 10.1055/a-1498-2512] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
3 Shen Y, Qi J, Wang Y, Chen J, Fan Y, Wang Y, Wu D, Xu Y. Hepatitis B immunoglobulin (HBIG) combined with long-term entecavir prophylaxis for hepatitis B virus infection in allogeneic hematopoietic stem cell transplantation with hepatitis B surface antigen-positive donors. Leuk Lymphoma 2021;62:2284-7. [PMID: 33733985 DOI: 10.1080/10428194.2021.1901095] [Reference Citation Analysis]
4 Giaccone L, Felicetti F, Butera S, Faraci D, Cerrano M, Dionisi Vici M, Brunello L, Fortunati N, Brignardello E, Bruno B. Optimal Delivery of Follow-Up Care After Allogeneic Hematopoietic Stem-Cell Transplant: Improving Patient Outcomes with a Multidisciplinary Approach. J Blood Med 2020;11:141-62. [PMID: 32523389 DOI: 10.2147/JBM.S206027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
5 Gentile G, Antonelli G. HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review. Viruses. 2019;11. [PMID: 31717647 DOI: 10.3390/v11111049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
6 Zannella A, Marignani M, Begini P. Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management. Viruses 2019;11:E858. [PMID: 31540124 DOI: 10.3390/v11090858] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Transplant Recipients. Clin Liver Dis 2019;23:493-509. [PMID: 31266623 DOI: 10.1016/j.cld.2019.04.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Zappulo E, Nicolini LA, Di Grazia C, Dominietto A, Lamparelli T, Gualandi F, Caligiuri P, Bruzzone B, Angelucci E, Viscoli C, Mikulska M. Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab. Infection 2019;47:59-65. [PMID: 30232604 DOI: 10.1007/s15010-018-1214-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
9 Cholongitas E, Haidich AB, Apostolidou-Kiouti F, Chalevas P, Papatheodoridis GV. Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. Ann Gastroenterol. 2018;31:480-490. [PMID: 29991894 DOI: 10.20524/aog.2018.0266] [Cited by in Crossref: 6] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
10 Siyahian A, Malik SU, Mushtaq A, Howe CL, Majeed A, Zangeneh T, Iftikhar S, Habib S, Zahid U, Riaz IB, Warraich Z, Faridi W, Anwer F. Prophylaxis for Hepatitis B Virus Reactivation after Allogeneic Stem Cell Transplantation in the Era of Drug Resistance and Newer Antivirals: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant 2018;24:1483-9. [PMID: 29545185 DOI: 10.1016/j.bbmt.2018.02.027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
11 Nicolini LA, Zappulo E, Viscoli C, Mikulska M. Management of chronic viral hepatitis in the hematological patient. Expert Rev Anti Infect Ther 2018;16:227-41. [PMID: 29415584 DOI: 10.1080/14787210.2018.1438264] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
12 Marrone A, Capoluongo N, D'Amore C, Pisaturo M, Esposito M, Guastafierro S, Siniscalchi I, Macera M, Boemio A, Onorato L, Rinaldi L, Minichini C, Adinolfi LE, Sagnelli E, Mastrullo L, Coppola N. Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy. J Viral Hepat. 2018;25:198-204. [PMID: 29029365 DOI: 10.1111/jvh.12802] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
13 Grossi G, Viganò M, Facchetti F, Labanca S, Loglio A, Dodero A, Montefusco V, Corradini P, Cafro A, Cairoli R, Colombo M, Lampertico P. Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies: two case reports. Haematologica 2017;102:e423-6. [PMID: 28659333 DOI: 10.3324/haematol.2017.168609] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
14 Gentile G, Andreoni M, Antonelli G, Sarmati L. Screening, monitoring, prevention, prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation: a systematic review. Clin Microbiol Infect 2017;23:916-23. [PMID: 28668465 DOI: 10.1016/j.cmi.2017.06.024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
15 Cerva C, Colagrossi L, Maffongelli G, Salpini R, Di Carlo D, Malagnino V, Battisti A, Ricciardi A, Pollicita M, Bianchi A, Picardi A, Cudillo L, Cerretti R, De Angelis G, Cantonetti M, Andreoni M, Perno CF, Arcese W, Svicher V, Sarmati L. Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor. Clin Microbiol Infect 2016;22:946.e1-8. [PMID: 27475741 DOI: 10.1016/j.cmi.2016.07.021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
16 Pompili M, Basso M, Hohaus S, Bosco G, Nosotti L, D’andrea M, Fenu S, Grieco A, Laurenti L, Mirisola C, Pagano L, Rapaccini GL, Sica S, Storti S, Landolfi R. Prospective study of hepatitis B virus reactivation in patients with hematological malignancies. Annals of Hepatology 2015;14:168-74. [DOI: 10.1016/s1665-2681(19)30778-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
17 Gupta A, Punatar S, Gawande J, Bagal B, Mathew L, Bhat V, Kannan S, Khattry N. Hepatitis B-related serological events in hematopoietic stem cell transplant patients and efficacy of lamivudine prophylaxis against reactivation. Hematol Oncol 2016;34:140-6. [PMID: 25690950 DOI: 10.1002/hon.2195] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
18 Mikulska M, Nicolini L, Signori A, Rivoli G, Del Bono V, Raiola A, Di Grazia C, Dominietto A, Varaldo R, Ghiso A, Bacigalupo A, Viscoli C. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome. Clinical Microbiology and Infection 2014;20:O694-701. [DOI: 10.1111/1469-0691.12611] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 6.5] [Reference Citation Analysis]
19 Takahata M, Hashino S, Onozawa M, Shigematsu A, Sugita J, Fujimoto K, Endo T, Kondo T, Tanaka J, Imamura M, Teshima T. Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non-responders to hepatitis B vaccine after allogeneic stem cell transplantation: long-term analysis of intervention in RS with vaccine for patients with previous HBV infection. Transpl Infect Dis. 2014;16:797-801. [PMID: 25154638 DOI: 10.1111/tid.12283] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
20 Aoki J, Kimura K, Kakihana K, Ohashi K, Sakamaki H. Efficacy and tolerability of Entecavir for hepatitis B virus infection after hematopoietic stem cell transplantation. Springerplus. 2014;3:450. [PMID: 25184113 DOI: 10.1186/2193-1801-3-450] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
21 Cheung MC, Agarwal K. Liver abnormalities in the immunosuppressed. Best Practice & Research Clinical Gastroenterology 2013;27:597-618. [DOI: 10.1016/j.bpg.2013.06.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Yaşar DG, Suyanı E, Özenirler S, Sucak GT. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report. Transplant Proc 2013;45:833-4. [PMID: 23498831 DOI: 10.1016/j.transproceed.2012.06.082] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
23 Chen S, Wang T, Yang K. Hematopoietic stem cell donation. Int J Hematol 2013;97:446-55. [DOI: 10.1007/s12185-013-1298-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
24 Mandalà M, Fagiuoli S, Francisci D, Bruno R, Merelli B, Pasulo L, Tondini C, Labianca R, Roila F. Hepatitis B in immunosuppressed cancer patients: pathogenesis, incidence and prophylaxis. Crit Rev Oncol Hematol 2013;87:12-27. [PMID: 23313021 DOI: 10.1016/j.critrevonc.2012.12.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
25 Tomblyn M, Chen M, Kukreja M, Aljurf MD, Al Mohareb F, Bolwell BJ, Cahn JY, Carabasi MH, Gale RP, Gress RE, Gupta V, Hale GA, Ljungman P, Maziarz RT, Storek J, Wingard JR, Young JA, Horowitz MM, Ballen KK. No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation. Transpl Infect Dis 2012;14:468-78. [PMID: 22548788 DOI: 10.1111/j.1399-3062.2012.00732.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
26 Marignani M, Canzoni M, D'Amelio R, De Santis E, Pecchioli A, Delle Fave G. Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? NO. Eur J Intern Med 2011;22:576-81. [PMID: 22075283 DOI: 10.1016/j.ejim.2011.09.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
27 Marinone C, Mestriner M. HBV disease: HBsAg carrier and occult B infection reactivation in haematological setting. Dig Liver Dis. 2011;43 Suppl 1:S49-S56. [PMID: 21195372 DOI: 10.1016/s1590-8658(10)60692-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]